Chemotherapy of endometrial cancer -E.V. Bakhidze, A.V. Belyaeva 29 Optimal tactics of adjuvant treatment of patients with endometrial cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents an overview of the current literature data on the problem of chemotherapy of endometrial cancer (EC). The available data on the use of adjuvant chemotherapy in combined treatment of EC have been analyzed, and they demonstrated its effectiveness in combination with radiation therapy at I, II, III stages and high risk of recurrence of the disease. The latest ESMO, ESGO, ESTRO, NCCN, and RUSSCO recommendations on adjuvant, systemic and palliative chemotherapy are discussed.

Full Text

Restricted Access

About the authors

S. V Khokhlova

FSBI “SRI of Oncology n.a. N.N. Petrov" of RMH; North-West State Medical University n.a. I.I. Mechnikov

Email: bakhidze@yandex.ru
MD, Leading Researcher at the Scientific Department of Oncogynecology; Associate Professor at the Department of Obstetrics and Gynecology

I. Ya Bazaeva

FSBI “SRI of Oncology n.a. N.N. Petrov" of RMH; SBHCI “St. Petersburg Clinical Scientific and Practical Center of Specialized Types of Medical Care (Oncological)“

Email: bakhidze@yandex.ru

References

  1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017. 250 с.
  2. Злокачественные новообразования в Санкт-Петербурге и других административных территориях Северо-Западного федерального округа России (заболеваемость, смертность, контингенты, выживаемость, больных). Экспресс-информация. Второй выпуск / Под ред. А.М. Беляева, Г.М. Манихаса, В.М. Мерабишвили. СПб., 2016. 208 с.
  3. Howlader N., Noone A.M., Krapcho M., et al. B.K. Edwards (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer institute. Bethesda, MD, http://seer.cancer.gov/ csr/1975_2008.
  4. Нечушкина В.М., Морхов К.Ю., Кузнецов В.В. Комбинированное лечение рака тела матки ранних стадий. Сиб. онкол. журн. 2013;3(57).
  5. Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., Heintz A.P., Ngan H.Y., Pecorelli S. Carcinoma of the Corpus Uteri. Int. J. Gynaecol. Obstet. 2006; 95(Suppl. 1):105-44.
  6. Blake P., Swart A.M., Orton J., Kitchener H., Whelan T., Lukka H., Eisenhauer E., Bacon M., Tu D., Parmar M.K., Amos C., Murray C., Qian W. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MPC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and metaanalysis. Lancet. 2009;373:137-46.
  7. Kong A., Johnson N., Kitchener H.C., Lawrie T.A. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J. Natl. Cancer Inst. 2012;104:1625-34.
  8. Bendifallah S., Canlorbe G., Paimond E., Hudry D., Coutant C., Graesslin O., Touboul C., Huguet F., Cortez A., Dara E., Ballester M. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br. J. Cancer. 2014;110:2640-46.
  9. Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., Pearlman A., Maiman M.A., Bell J.G. A phase III trial of surgery with or without adjunctive external pelvic radiation herapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Groupstudy. Gynecol. Oncol. 2004;92:744-51.
  10. Blake P., Swart A.M., Orton J., et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137-46.
  11. Bosse T., Peters E.E., Creutzberg C.L., Jürgenliemk-Schulz I.M., Jobsen J.J., Mens J.W., Luitgens L.C., van der Steen-Banasik E.M., Smit V.T., Nout R.A. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer-apooled analysis of PORTEC 1 and 2 trials. Eur. J. Cancer. 2015;51:1742-50.
  12. Soong R., Knowles S., Williams K.E., Hammond I.G., Wysocki S.J., Iacopetta B.J. Overexpression of p53 protein is an independent prognosticindicator in human endometrial carcinoma. Br. J. Cancer. 1996;74:562-67.
  13. Zeimet A.G., Reimer D., Huszar M., et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J. Natl. Cancer Inst. 2013;105.
  14. Talhouk A., McAlpine J.N. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol. Oncol. Res. Pract. 2016;3:14. doi: 10.1186/s40661-016-0035-4.
  15. Colombo N., Creutzberg C., Amant F., Bosse T., Gonzlez-Martn A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., Sessa C. ESMO-ESGO-ESTRO Consensus Conferenc on Endometrial Cancer: diagnosis, treatment and follow-up. Ann. Oncol. 2016;27:16-41.
  16. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2004;22:2159-66.
  17. Miller D., Filiaci V., Fleming G., et al. Late-Breaking Abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2012;125:771.
  18. McMeekin D.S., Filiaci V.L., Aghajanian C., et al. A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/ carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol. Oncol. 2014;134:438 (Abstr. LBA 431).
  19. Morrow C.P., Bundy B.N., Homesley H.D., Creasman W.T., Hornback N.B., Kurman R., Thigpen J.T. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol. Oncol. 1990;36:166-71.
  20. Maggi R., Lissoni A., Spina F., Melpignano M., Zola P., Favalli G., Colombo A., Fossati R. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br. J. Cancer. 2006;95:266-71.
  21. Susumu N., Sagae S., Udagawa Y., Niwa K., Kuramoto H., Satoh S., Kudo R. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol. Oncol. 2008;108:226-33.
  22. Greven K., Winter K., Underhill K., Fontenesci J., Cooper J., Burke T. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004;59(1):168-73.
  23. Greven K., Winter K., Underhill K., Fontenesci J., Cooper J., Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol. Oncol. 2006;103:155-59.
  24. Hogberg T., Signorelli M., de Oliveira C.F., et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur. J. Cancer. 2010;46:2422-31.
  25. Geller M.A., Ivy J.J., Ghebre R., Downs L.S. Jr, Judson P.L., Carson L.F., Jonson A.L., Dusenbery K., Vogel R.I., Boente M.P., Argenta P.A. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a «Sandwich» method for stage III, IV, and recurrent endometrial cancer. Gynecol. Oncol. 2011;121(1):112-17.
  26. Glasgow M., Vogel R.I., Burgart J., Argenta P., Dusenbery K., Geller M.A. Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol. Oncol. Res. Pract. 2016;3:6.
  27. De Boer S.M., Powell M.E., Mileshkin L., et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology. 2016;17:1114-26.
  28. NCCN Clinical Practice Guidelines In Oncology Uterine Neoplasms. Version 1.2017 https:// www.nccn.org/professionals/physician_gls/ pdf/uterine.pdf.
  29. Практические рекомендации RU SSCO -электронный ресурс. http://www.rosoncoweb.ru/ standarts/RUSSCO/2016/12.pdf.
  30. Nagao S., Nishio S., Michimae H., Tanabe H., Okada S., Otsuki T., Tanioka M., Fujiwara K., Suzuki M., Kigawa J. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/ Intergroup study. Gynecol. Oncol. 2013;131:567-73.
  31. Moore K.N., Tian C., McMeekin D.S., Thigpen J.T., Randall M.E., Gallion H.H. Does the progressionfree interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? A Gynecologic Oncology Group ancillary data analysis. Cancer. 2010;116:5407-14.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies